Company news

Cabaletta Bio, Inc. news in 2026

Cabaletta Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

November 5, 2026

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 4, 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences

November 3, 2026

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences

September 1, 2026

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

June 3, 2026

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

May 4, 2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

April 28, 2026

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

April 28, 2026

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

April 27, 2026

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 22, 2026

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 5, 2026

Cabaletta Bio Announces 2026 Strategic Priorities

January 12, 2026

Decks in 2026